homevideos Newshealthcare News20 25% topline growth, 200 250 bps improvement in margins expected, says Sequent Scientific
20-25% topline growth, 200-250 bps improvement in margins expected, says Sequent Scientific
Sequent Scientific is in focus as the company recently demerged its human active pharmaceutical ingredients (API) business into separate company, Solara Active Pharma.
Manish Gupta, CEO of Sequent Scientific said that the relisting process was on and expected the listing to occur by the end of May.
“Last quarter we had declared our continuing operations results and on that basis, we were clocking a quarterly revenue of about Rs 225 crore which is annualized to Rs 900 crore,” he said.
Talking about margin, he said, “we are very bullish on animal health business... we are targeting between 20-25 percent topline growth and 200-250 bps improvement in our EBTIDA margin year-on-year in the medium-term.”
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!
Gonda Lok Sabha election: BJP's Kirti Vardhan Singh takes on Beni Prasad Verma's granddaughter Shreya
May 19, 2024 10:19 PM
Faizabad Lok Sabha election: Can Ayodhya Ram Temple strengthen BJP's stronghold here?
May 19, 2024 10:16 PM
Amethi Lok Sabha election: Can BJP's Smriti Irani retain the Congress bastion she won in 2019?
May 19, 2024 10:12 PM
Rae Bareli Lok Sabha Election: Can Rahul hold on to this Gandhi family bastion?
May 19, 2024 10:09 PM